MS Market Outlook Good for Prescription Drugs List Medication, Alemtuzumab
Get instant savings up to 75%
Download the Free PrescriptionDrugs.com Discount Drug Card
Print Card
Redeem for instant savings up to 75% on name brand
& generic prescription drugs
Accepted at over 60,000 pharmacies nationwide
Prescription Drugs List News - Genzyme Corporation, a leading biotechnology firm focused on rare inherited disorders has revealed intense market research on Alemtuzumab; a prescription drug developed for use in the treatment of Multiple Sclerosis (MS). Alemtuzumab has several features making the prescription drug attractive to providers and patients.
Alemtuzumab Requires Annual Dosing
Genzyme’s research forecasts an uptake of Alemtuzumab in the MS market among physicians, patients and medical bill-payers, due to the prescription drug’s potential to fulfill currently unmet needs in the treatment of MS. Providers, patients and medical bill-payers want a treatment option that offers improved effectiveness, patient tolerance and patient convenience. Alemtuzumab’s successful second phase clinical trials indicate that it meets all three needs. According to Ed Fox, M.D, PhD, Director of the MS Clinic of Central Texas, “Alemtuzumab has the potential to improve function as well as halt the accumulation of disability and relapses, setting a new bar for MS treatment efficacy.”
Five years after Alemtuzumab’s second phase clinical trial, follow-up findings detail relapse and disability reductions as compared to competing treatments. These benefits were found to continue several years after patients received their final Alemtuzumab treatment courses. The decreased relapse and disability effects, combined with a new annual dosing schedule, is exciting for physicians and MS patients. It is believed that an annual treatment schedule will improve compliance, convenience and patient tolerance. Furthermore, use of this prescription drugs list medication should result in a reduction of chronic care costs, including fewer hospital re-admissions and less expense as a result of disability care.
